ICG-318

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameICG-318
Drug Alias NameICG318ICG-318
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD19 modulatorsB-cell maturation protein modulators
TargetsB-lymphocyte antigen CD19B-cell maturation protein
Therapy Area/IndicationsLupus Erythematosus, SystemicLupus NephritisInflammatory Bowel Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSonghe Immunobiological Medical (Shenzhen) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSonghe Immunobiological Medical (Shenzhen) Co LtdiCell ImmunityX（Hangzhou）Co LtdiCell Gene Therapeutics LLC +[4] 
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicLupus NephritisInflammatory Bowel Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A